CR7876A - Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen - Google Patents

Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Info

Publication number
CR7876A
CR7876A CR7876A CR7876A CR7876A CR 7876 A CR7876 A CR 7876A CR 7876 A CR7876 A CR 7876A CR 7876 A CR7876 A CR 7876A CR 7876 A CR7876 A CR 7876A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
compositions containing
preparation
procedure
crystal form
Prior art date
Application number
CR7876A
Other languages
English (en)
Inventor
Stephane Horbath
Isabelle Demuynck
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7876(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR7876A publication Critical patent/CR7876A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion se refiere a la forma cristalina alfa del renelato de estroncio, a su procedimiento de preparacion asi como a las composiciones farmaceuticas que la contienen.
CR7876A 2004-09-30 2005-06-15 Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen CR7876A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
CR7876A true CR7876A (es) 2007-12-10

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7876A CR7876A (es) 2004-09-30 2005-06-15 Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Country Status (42)

Country Link
US (2) US7459568B2 (es)
EP (2) EP1944302A1 (es)
JP (2) JP2006104184A (es)
KR (1) KR100816590B1 (es)
CN (1) CN100391956C (es)
AP (1) AP1930A (es)
AR (1) AR049395A1 (es)
AT (1) ATE411308T1 (es)
AU (1) AU2005202718B2 (es)
BR (1) BRPI0502228A (es)
CA (1) CA2508824C (es)
CO (1) CO5710195A1 (es)
CR (1) CR7876A (es)
CY (1) CY1108797T1 (es)
DE (1) DE602005010359D1 (es)
DK (1) DK1642897T3 (es)
EA (1) EA008474B1 (es)
EC (1) ECSP055859A (es)
ES (1) ES2314593T3 (es)
FR (1) FR2875807B1 (es)
GE (1) GEP20074106B (es)
GT (1) GT200500130A (es)
HK (1) HK1086260A1 (es)
HR (1) HRP20080652T3 (es)
IL (1) IL169237A (es)
MA (1) MA27815A1 (es)
MX (1) MXPA05006407A (es)
NO (1) NO333948B1 (es)
NZ (1) NZ540802A (es)
OA (1) OA13013A (es)
PA (1) PA8638201A1 (es)
PE (1) PE20060364A1 (es)
PL (1) PL1642897T3 (es)
PT (1) PT1642897E (es)
RS (1) RS51110B (es)
SA (1) SA05260168B1 (es)
SG (1) SG121035A1 (es)
SI (1) SI1642897T1 (es)
TW (1) TWI367881B (es)
UA (1) UA80008C2 (es)
WO (1) WO2006035122A1 (es)
ZA (1) ZA200504937B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
EP2346846A1 (en) 2008-09-29 2011-07-27 Ratiopharm GmbH Anhydrate and hydrate forms of strontium ranelate
IT1398542B1 (it) 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
US9301945B2 (en) 2011-07-21 2016-04-05 Emory University Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
IL161164A0 (en) * 2001-10-03 2004-08-31 Teva Pharma Preparation of levofloxacin and forms thereof
EP2272501B1 (en) * 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
JP2006508909A (ja) * 2002-08-06 2006-03-16 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規な結晶形
FR2844797B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844796A1 (fr) * 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
KR20060049966A (ko) 2006-05-19
AR049395A1 (es) 2006-07-26
BRPI0502228A (pt) 2006-05-09
EP1642897B9 (fr) 2009-08-12
JP2006104184A (ja) 2006-04-20
HK1086260A1 (en) 2006-09-15
EP1642897B1 (fr) 2008-10-15
GEP20074106B (en) 2007-05-10
ECSP055859A (es) 2006-09-18
US7459568B2 (en) 2008-12-02
WO2006035122A1 (fr) 2006-04-06
ZA200504937B (en) 2006-04-26
TWI367881B (en) 2012-07-11
AU2005202718A1 (en) 2006-04-13
CY1108797T1 (el) 2014-04-09
MA27815A1 (fr) 2006-04-03
DK1642897T3 (da) 2009-01-26
ES2314593T3 (es) 2009-03-16
GT200500130A (es) 2005-12-20
FR2875807A1 (fr) 2006-03-31
RS51110B (sr) 2010-10-31
IL169237A (en) 2010-12-30
JP2010132669A (ja) 2010-06-17
PA8638201A1 (es) 2006-05-16
US7745482B2 (en) 2010-06-29
NO20052998L (no) 2006-03-31
DE602005010359D1 (de) 2008-11-27
OA13013A (fr) 2006-11-10
AU2005202718B2 (en) 2010-09-16
NZ540802A (en) 2006-11-30
HRP20080652T3 (en) 2009-01-31
SI1642897T1 (sl) 2009-02-28
TW200610758A (en) 2006-04-01
US20080312314A1 (en) 2008-12-18
CA2508824A1 (fr) 2006-03-30
CN1754878A (zh) 2006-04-05
CN100391956C (zh) 2008-06-04
PT1642897E (pt) 2008-11-27
FR2875807B1 (fr) 2006-11-17
US20060069271A1 (en) 2006-03-30
PE20060364A1 (es) 2006-06-17
SG121035A1 (en) 2006-04-26
CO5710195A1 (es) 2006-12-29
SA05260168B1 (ar) 2009-02-25
NO333948B1 (no) 2013-10-28
PL1642897T3 (pl) 2009-04-30
EA008474B1 (ru) 2007-06-29
ATE411308T1 (de) 2008-10-15
EP1642897A1 (fr) 2006-04-05
EA200500842A1 (ru) 2006-04-28
NO20052998D0 (no) 2005-06-17
AP1930A (en) 2008-12-15
UA80008C2 (uk) 2007-08-10
EP1944302A1 (fr) 2008-07-16
CA2508824C (fr) 2009-03-24
AP2005003323A0 (en) 2005-06-30
MXPA05006407A (es) 2006-04-05
KR100816590B1 (ko) 2008-03-24

Similar Documents

Publication Publication Date Title
CR7876A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
NI200600240A (es) FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CR8249A (es) Forma cristalina gamma del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen
ECSP066374A (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
PA8671301A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
NI201000013A (es) Sulfonamidas como moduladores del trpm8
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
UY30931A1 (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso
UY32072A (es) Tienopirimidinas para composiciones farmacéuticas
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
CR10557A (es) Bencilaminas, un proceso para la produccion y su uso como agentes antiinflamatorios
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
ECSP11010816A (es) Nuevos Compuestos

Legal Events

Date Code Title Description
FC Refusal